Cash Flow Orchid Pharma Cash flow Statement
Figures in Cr
Consolidated Cash Flow Results
Mar'25
Mar'24
Mar'23
Mar'22
Mar'21
Mar'20
No of Months
12
12
12
12
12
12
Profit Before Tax
99.00
89.00
46.00
-1.00
-116.00
-131.00
Adjustment
29.00
44.00
51.00
36.00
172.00
139.00
Changes In working Capital
-108.00
-7.00
-79.00
59.00
-36.00
61.00
Cash Flow after changes in Working Capital
20.00
125.00
18.00
94.00
18.00
70.00
Cash Flow from Operating Activities
19.00
125.00
18.00
92.00
23.00
80.00
Cash Flow from Investing Activities
-26.00
-312.00
-31.00
112.00
67.00
167.00
Cash Flow from Financing Activities
25.00
167.00
31.00
-216.00
-164.00
-250.00
Net Cash Inflow / Outflow
17.00
-19.00
18.00
-11.00
-74.00
-2.00
Opening Cash & Cash Equivalents
3.00
22.00
4.00
15.00
89.00
92.00
Cash & Cash Equivalent on Amalgamation / Take over / Merger
0.00
0.00
0.00
0.00
0.00
0.00
Cash & Cash Equivalent of Subsidiaries under liquidations
0.00
0.00
0.00
0.00
0.00
0.00
Translation adjustment on reserves / op cash balances foreign subsidiaries
0.00
0.00
0.00
0.00
0.00
0.00
Effect of Foreign Exchange Fluctuations
0.00
0.00
0.00
0.00
0.00
0.00
Closing Cash & Cash Equivalent
21.00
3.00
22.00
4.00
15.00
89.00
Figures in INR Cr
Seasonal companies are compared with the same quarter last year
Seasonal companies are compared with the same quarter last year
Compare Cash Flow Results of Orchid Pharma
Figures in Cr
standaloned Cash Flow Results
Change(INR)
Change(%)
Profit Before Tax
106.48
65.54
41.00
62.47%
Adjustment
23.52
5.09
18.00
362.08%
Changes In working Capital
-101.58
36.88
-137.00
-375.43%
Cash Flow after changes in Working Capital
28.42
107.51
-79.00
-73.57%
Cash Flow from Operating Activities
27.48
91.03
-64.00
-69.81%
Cash Flow from Investing Activities
-37.35
-111.82
74.00
66.60%
Cash Flow from Financing Activities
25.44
26.01
-1.00
-2.19%
Net Cash Inflow / Outflow
15.58
5.22
10.00
198.47%
Opening Cash & Cash Equivalents
0.29
6.47
-6.00
-95.52%
Cash & Cash Equivalent on Amalgamation / Take over / Merger
0
0
0.00
0.00%
Cash & Cash Equivalent of Subsidiaries under liquidations
0
0
0.00
0.00%
Translation adjustment on reserves / op cash balances foreign subsidiaries
0
0
0.00
0.00%
Effect of Foreign Exchange Fluctuations
0
0
0.00
0.00%
Closing Cash & Cash Equivalent
15.87
11.69
4.00
35.76%
Cash Flow - Snapshot (Consolidated) - Mar'25
YoY Growth in year ended Mar 2025 is -84.74% vs 586.97% in Mar 2024
Mar'25
Mar'24
Change(%)
Cash Flow from Operating Activities
19.22
125.99
-84.74%
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
